Xilio Therapeutics (XLO) Capital Expenditures Growth (1y) (2021 - 2026)
Xilio Therapeutics (XLO) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 143.40% |
| 10 | Xilio Therapeutics | 145.98 Mn | -4.32 Mn | - | 90.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 90.41% |
| Dec 31, 2025 | 233.33% |
| Mar 31, 2025 | 1,290.48% |
| Mar 31, 2024 | -87.65% |
| Jun 30, 2023 | -59.01% |
| Mar 31, 2023 | -33.07% |
| Dec 31, 2022 | -372.15% |
| Sep 30, 2022 | 159.36% |
| Jun 30, 2022 | 76.03% |
| Mar 31, 2022 | 49.41% |
| Dec 31, 2021 | 355.56% |